In the aftermath of announcing a major collaboration with Sandoz on biosimilars, Evotec’s chief business officer Matthias Evers speaks to Generics Bulletin about how the deal provides “validation” of Just-Evotec’s technology platform, while also outlining the firm’s wider ambitions to enable more efficient development of and broader access to biologics.
In a major deal for the off-patent industry, Sandoz recently announced a multi-year collaboration with Evotec subsidiary Just-Evotec Biologics that will see the firms develop and manufacture multiple biosimilars together.
The alliance – which Sandoz’s biosimilars head told Generics Bulletin would be “a game-changer” for the firm’s biopharma business (Also...
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
